Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, November 2, 2022
[ Wed, Nov 02nd 2022
] - WOPRAI
[ Wed, Nov 02nd 2022
] - WOPRAI
[ Wed, Nov 02nd 2022
] - WOPRAI
[ Wed, Nov 02nd 2022
] - WOPRAI
[ Wed, Nov 02nd 2022
] - WOPRAI
[ Wed, Nov 02nd 2022
] - WOPRAI
[ Wed, Nov 02nd 2022
] - WOPRAI
Tue, November 1, 2022
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
[ Tue, Nov 01st 2022
] - WOPRAI
Etzer Darout Maintained (YMAB) at Buy with Decreased Target to $12 on, Nov 1st, 2022
Etzer Darout of BMO Capital, Maintained "Y-mAbs Therapeutics, Inc." (YMAB) at Buy with Decreased Target from $29 to $12 on, Nov 1st, 2022.
Etzer has made no other calls on YMAB in the last 4 months.
There are 5 other peers that have a rating on YMAB. Out of the 5 peers that are also analyzing YMAB, 2 agree with Etzer's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- David Nierengarten of "Wedbush" Downgraded from Buy to Hold and Held Target at $6 on, Monday, October 31st, 2022
- Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $8 on, Monday, October 31st, 2022
These are the ratings of the 3 analyists that currently disagree with Etzer
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $19 on, Monday, October 31st, 2022
- Tessa Romero of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $7 on, Monday, October 31st, 2022
- William Maughan of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $27 on, Monday, October 31st, 2022
